159 related articles for article (PubMed ID: 11023974)
41. Modulation of signal transducer and activator of transcription 3 activities by p53 tumor suppressor in breast cancer cells.
Lin J; Jin X; Rothman K; Lin HJ; Tang H; Burke W
Cancer Res; 2002 Jan; 62(2):376-80. PubMed ID: 11809683
[TBL] [Abstract][Full Text] [Related]
42. [New transcription factor-based cancer therapy. Gene therapy, cell lysis, reactivation of p53 are the new approaches].
Wiman KG
Lakartidningen; 1997 Sep; 94(38):3268-72. PubMed ID: 9379794
[TBL] [Abstract][Full Text] [Related]
43. Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants.
Zalcenstein A; Stambolsky P; Weisz L; Müller M; Wallach D; Goncharov TM; Krammer PH; Rotter V; Oren M
Oncogene; 2003 Aug; 22(36):5667-76. PubMed ID: 12944915
[TBL] [Abstract][Full Text] [Related]
44. Loss of function and p53 protein stabilization.
Blagosklonny MV
Oncogene; 1997 Oct; 15(16):1889-93. PubMed ID: 9365234
[TBL] [Abstract][Full Text] [Related]
45. Chaperoning of mutant p53 protein by wild-type p53 protein causes hypoxic tumor regression.
Gogna R; Madan E; Kuppusamy P; Pati U
J Biol Chem; 2012 Jan; 287(4):2907-14. PubMed ID: 22147694
[TBL] [Abstract][Full Text] [Related]
46. Network effect of Wt-mutant p53 interactions and implications on p53 gene therapy.
Ji X; Ma L; Huang Q; Li Z; Zhao J; Huang W; Ma B; Yu L
Curr Pharm Des; 2014; 20(8):1259-67. PubMed ID: 23713777
[TBL] [Abstract][Full Text] [Related]
47. Wild-type p53 oligomerizes more efficiently than p53 hot-spot mutants and overcomes mutant p53 gain-of-function via a "dominant-positive" mechanism.
Walerych D; Pruszko M; Zyla L; Wezyk M; Gaweda-Walerych K; Zylicz A
Oncotarget; 2018 Aug; 9(62):32063-32080. PubMed ID: 30174797
[TBL] [Abstract][Full Text] [Related]
48. Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor.
Silva JL; Rangel LP; Costa DC; Cordeiro Y; De Moura Gallo CV
Biosci Rep; 2013 Jul; 33(4):. PubMed ID: 24003888
[TBL] [Abstract][Full Text] [Related]
49. The Contrived Mutant p53 Oncogene - Beyond Loss of Functions.
Sabapathy K
Front Oncol; 2015; 5():276. PubMed ID: 26697411
[TBL] [Abstract][Full Text] [Related]
50. p53 dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells.
Dong P; Tada M; Hamada J; Nakamura A; Moriuchi T; Sakuragi N
Clin Exp Metastasis; 2007; 24(6):471-83. PubMed ID: 17636407
[TBL] [Abstract][Full Text] [Related]
51. Cancer-derived C-terminus-extended p53 mutation confers dominant-negative effect on its wild-type counterpart.
Huang S; Cao B; Wang J; Zhang Y; Ledet E; Sartor O; Xiong Y; Zeng SX; Lu H
J Mol Cell Biol; 2022 Mar; 14(1):. PubMed ID: 34918105
[TBL] [Abstract][Full Text] [Related]
52. Dosage-dependent dominance over wild-type p53 of a mutant p53 isolated from nasopharyngeal carcinoma.
Sun Y; Dong Z; Nakamura K; Colburn NH
FASEB J; 1993 Jul; 7(10):944-50. PubMed ID: 8344492
[TBL] [Abstract][Full Text] [Related]
53. Targeting mutant p53 stabilization for cancer therapy.
Wang J; Liu W; Zhang L; Zhang J
Front Pharmacol; 2023; 14():1215995. PubMed ID: 37502209
[TBL] [Abstract][Full Text] [Related]
54. A chimeric p53 evades mutant p53 transdominant inhibition in cancer cells.
Okal A; Mossalam M; Matissek KJ; Dixon AS; Moos PJ; Lim CS
Mol Pharm; 2013 Oct; 10(10):3922-33. PubMed ID: 23964676
[TBL] [Abstract][Full Text] [Related]
55. Mutant p53 oncogenicity: dominant-negative or gain-of-function?
Stein Y; Aloni-Grinstein R; Rotter V
Carcinogenesis; 2020 Dec; 41(12):1635-1647. PubMed ID: 33159515
[TBL] [Abstract][Full Text] [Related]
56. Elucidating the Mechanisms of R248Q Mutation-Enhanced p53 Aggregation and Its Inhibition by Resveratrol.
Liu Q; Li L; Yu Y; Wei G
J Phys Chem B; 2023 Sep; 127(36):7708-7720. PubMed ID: 37665658
[TBL] [Abstract][Full Text] [Related]
57. Regulation of Mutant p53 Protein Expression.
Vijayakumaran R; Tan KH; Miranda PJ; Haupt S; Haupt Y
Front Oncol; 2015; 5():284. PubMed ID: 26734569
[TBL] [Abstract][Full Text] [Related]
58. p53: Multiple Facets of a Rubik's Cube.
Zhang Y; Lozano G
Annu Rev Cancer Biol; 2017 Mar; 1():185-201. PubMed ID: 30775651
[TBL] [Abstract][Full Text] [Related]
59. Mutant p53: One, No One, and One Hundred Thousand.
Walerych D; Lisek K; Del Sal G
Front Oncol; 2015; 5():289. PubMed ID: 26734571
[TBL] [Abstract][Full Text] [Related]
60. p53, A Victim of the Prion Fashion.
Billant O; Friocourt G; Roux P; Voisset C
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33450819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
